Navigation Links
Bone Biologics to Webcast, Live, at RetailInvestorConferences.com on September 12th
Date:9/10/2013

NEW YORK, Sept. 10, 2013 /PRNewswire/ -- Bone Biologics today announced that William Jay Treat, Ph.D., President and Chief Technology Officer, will present at RetailInvestorConferences.com.

DATE:   September 12, 2013

TIME:    11:45 AM EDT

LINK:    www.retailinvestorconferences.com > click on the red "register / watch event now" button

This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the company's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.

It is recommended that investors pre-register to save time and receive event updates.

About Bone Biologics:

Bone Biologics was founded by University of California professors in collaboration with an Osaka University professor and a USC Surgeon in 2004.  Bone Biologics is a privately-held company with proprietary, patented technology that has been clinically proven in non-human primate models to facilitate bone growth. The company is currently focused on bone regeneration in spinal fusion using its recombinant human protein, known as UCB-1 (or Nell-1). UCB-1 is an osteoinductive orthobiologic: a recombinant protein that provides control over bone regeneration. This patent protected technology has been exclusively licensed to Bone Biologics from UCLA.

About RetailInvestorConferences.com:

Since 2010, RetailInvestorConferences.com has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.


'/>"/>
SOURCE Bone Biologics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Synthetic Biologics to Present at the First Global Life Sciences Conference in Warsaw, Poland
2. Market Research Reports: Biologics, Biosimilars, Bioseparation Systems for Biopharmaceutical Markets
3. Oncobiologics and inVentiv Health Form Strategic Partnership around Biosimilars
4. Former Pfizer/Wyeth Global Infectious Disease Pharmaceutical Executive, Lewis Barrett, Appointed Senior Vice President, Commercial Strategy of Synthetic Biologics, Inc.
5. PharmAthene and Theraclone Sciences Announce Merger Agreement to Create Diversified Biologics Company Targeting Government and Commercial Markets
6. Water Street Completes Investment in RTI Biologics Inc.
7. For Moderate to Severe Psoriasis, Thought Leaders Opinions and Clinical Data Indicate That Emerging Biologics That Target IL-17 Have the Potential to Offer Improvements in Efficacy and Safety Over Current Therapies
8. Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohns Disease and Ulcerative Colitis in the United States
9. Synthetic Biologics to Host Multiple Sclerosis-Estriol Investor Day in New York City on June 25, 2013
10. Original Drugs Pave the Way for Follow-on Biologics
11. Biosimilars And Follow-On Biologics: World Market 2013-2023
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... 2017 Research and Markets has announced ... (Thermometers - Digital, Infrared, Mercury; Trend Indicator):Analysis By Region, By Country ... ... forecasted to grow at a CAGR of 5.33% during 2016-2021 ... infectious diseases along with surging demand of digital thermometer. Apart from ...
(Date:2/22/2017)... Feb. 22, 2017 Oncternal Therapeutics, Inc., ... both rare and common malignancies, today announced the ... The company intends to use the proceeds to ... and to advance preclinical development of a new ... is a first-in-class anti-ROR1 monoclonal antibody being developed ...
(Date:2/22/2017)... -- Kineta, Inc., a biotechnology company focused on ... today announced that KCP-400 (RgIA4), a potent antagonist ... robust chronic pain relief and disease modifying effects ... the a9a10 nAChR as a new, non-opioid target ... were reported online in the February 20 th ...
Breaking Medicine Technology:
(Date:2/22/2017)... , ... February 22, 2017 , ... A product of ... seem to derive a heart-protective benefit from eating soy foods, while others do not, ... men who are able to produce equol—a substance made by some types of “good” ...
(Date:2/22/2017)... ... February 22, 2017 , ... Forty-five percent ... those report that family members or friends have also commented about their poor ... loss wear hearing aids. One reason, suggested by 89 percent of American respondents, ...
(Date:2/22/2017)... , ... February 22, 2017 , ... Super-Sod will attend ... 26 event in Athens, Georgia. , A shift from Super-Sod’s simple Athens Home Show ... , For the booth, grass seed plant manager Chris Roquemore constructed furniture from recycled ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... Social media ... especially for hospitals and health systems. Smith & Jones’ delves into this insight and ... episode, President of Smith & Jones David Vener meets up with social media strategist ...
(Date:2/22/2017)... ... February 22, 2017 , ... BrightStar Care Charleston , a ... Medical University of South Carolina (MUSC) Center on Aging’s Senior Expo on Thursday, ... on Aging is a tremendous resource in our community. We are thrilled to participate ...
Breaking Medicine News(10 mins):